SC
CYTK icon

Stempoint Capital’s Cytokinetics CYTK Stock Holding History

Stempoint Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.44M Sell
75,603
-53,974
-42% -$3.88M 1.11% 32
2026
Q1 		$8.54M Sell
129,577
-17,401
-12% -$1.11M 1.64% 20
2025
Q4 		$9.34M Buy
+146,978
New +$9.14M 1.6% 19
2025
Q2 		– Sell
-149,648
Closed -$6.01M – 61
2025
Q1 		$6.01M Buy
149,648
+66,072
+79% +$3.04M 1.92% 23
2024
Q4 		$3.93M Buy
83,576
+69,112
+478% +$3.59M 0.98% 34
2024
Q3 		$764K Buy
+14,464
New +$806K 0.23% 47
2024
Q1 		– Sell
-24,111
Closed -$2.01M – 71
2023
Q4 		$2.01M Buy
+24,111
New +$873K 0.54% 50

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stempoint Capital's CYTK Position: Q2 2026 in Review

Stempoint Capital reduced its Cytokinetics (CYTK) stake by 42% in Q2 2026, selling an estimated $3.88M and leaving 75,603 shares worth $6.44M. The position accounts for 1.11% of the portfolio, ranked #32.

Stempoint Capital first reported a position in CYTK in Q4 2023 and has held it in 7 quarters since. The position peaked at $9.34M in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Stempoint Capital held 75,603 shares of Cytokinetics worth $6.44M as of Q2 2026.
  • Stempoint Capital sold 53,974 Cytokinetics shares in Q2 2026, an estimated $3.88M.
  • Cytokinetics made up 1.11% of Stempoint Capital's portfolio in Q2 2026, its #32 holding.
  • Stempoint Capital first reported a position in Cytokinetics in Q4 2023 and has held it in 7 quarters since.
  • Stempoint Capital's Cytokinetics position peaked at $9.34M in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.